{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-002853","form_type":"8-K","ticker":"AHCO","cik":"0001725255","company_name":"AdaptHealth Corp.","filed_at":"2023-01-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.324499+00:00","generated_at":"2026-06-20T16:36:36.057276+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"medium","headline":"AdaptHealth guides FY2023 revenue $3.21-3.29B, adj. EBITDA $690-750M; Q4 prelim near prior ranges","bullets":["FY2023 net revenue guidance $3.210B-3.290B; Adjusted EBITDA $690M-$750M; capex 9-11% of revenue.","FY2022 net revenue expected near midpoint of $2.950B-$3.010B; Adjusted EBITDA near low end of $620M-$650M.","Non-acquired net revenue growth for 2023 estimated at 8-10%, driven by stabilizing PAP device supply.","CEO cites strong demand but notes cost-of-goods inflation and labor pressures across healthcare.","Full Q4 and FY2022 results scheduled for release February 28, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-002853","json":"https://secwatch.observer/filing/0001104659-23-002853.json","markdown":"https://secwatch.observer/filing/0001104659-23-002853.md","text":"https://secwatch.observer/filing/0001104659-23-002853.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1725255/000110465923002853/0001104659-23-002853-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1725255/000110465923002853/tm233016d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T16:36:36.057276+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"445ed13e374ec9bfff9857f6107afe551326968d","claim":"AdaptHealth Corp. reported fiscal year 2023 results: revenue $3.210 billion to $3.290 billion. Guidance initiated.","evidence_excerpt":"Based on current business, market trends, and acquisitions completed to date, the Company is establishing initial guidance for fiscal year 2023 as follows: · Net revenue of $3.210 billion to $3.290 billion; · Adjusted EBITDA of $690 million to $750 million; and · Total capital expenditures are expected to be 9-11% of net revenue. Guidance for fiscal year 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1725255/000110465923002853/0001104659-23-002853-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fiscal year 2023"},{"label":"Revenue","value":"$3.210 billion to $3.290 billion"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"4eb83d401b6a6e5ef13105f41a68cff7eb51ab4c","claim":"AdaptHealth Corp. reported preliminary financial results for fourth quarter 2022.","evidence_excerpt":"ADAPTHEALTH PROVIDES Full-year 2023 Guidance AND Preliminary Commentary on Fourth Quarter 2022 REsults","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1725255/000110465923002853/0001104659-23-002853-index.htm","confidence":0.85,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter 2022"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"},{"claim_id":"65d2d384d308e994f332c4fecc44b6c0ad0a66c5","claim":"AdaptHealth Corp. reported full year 2022 results: revenue net revenue to be near the midpoint of the previously-provided guidance range of $2.950 billion to $3.010 billion.","evidence_excerpt":"the Company anticipates net revenue to be near the midpoint of the previously-provided guidance range of $2.950 billion to $3.010 billion","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1725255/000110465923002853/0001104659-23-002853-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full year 2022"},{"label":"Revenue","value":"net revenue to be near the midpoint of the previously-provided guidance range of $2.950 billion to $3.010 billion"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}